Suven Life Sciences Ltd

Suven Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Suven Life Sciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. Despite a recent upgrade in its technical outlook, the stock continues to display a complex interplay of indicator signals, reflecting both strength and caution for investors navigating the healthcare services sector.

Suven Life Sciences Ltd, a small-cap player in the Healthcare Services sector, has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a recent downgrade in its Mojo Grade to Sell from Strong Sell, the stock’s price momentum and technical indicators present a nuanced picture for investors navigating the current market environment.

Suven Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Surging past its previous peaks, Suven Life Sciences Ltd touched a new 52-week high of Rs 398.8 on 1 Sep 2026, marking a remarkable 92.18% gain over the past year. This milestone comes amid a backdrop of broad technical momentum that has propelled the stock well beyond its 52-week low of Rs 124.35, even as the broader market has struggled.

Suven Life Sciences Ltd, a player in the healthcare services sector, achieved a significant milestone on 1 September 2026 by reaching its all-time high stock price of Rs.397.95. This peak reflects a sustained period of strong performance and bullish technical indicators, marking a notable moment in the company’s market journey.

Surging to an intraday peak of Rs 394.95 on 31 Aug 2026, Suven Life Sciences Ltd has marked a significant milestone by hitting a fresh 52-week high. This rally comes amid a backdrop of strong technical momentum, with the stock outperforming its sector by 7.86% today and trading well above all key moving averages.

Suven Life Sciences Ltd has reached a significant milestone by touching its all-time high price of Rs 394.70 on 31 August 2026, marking a remarkable surge in the healthcare services sector. This achievement reflects the company’s sustained market momentum and notable outperformance against key benchmarks.

The Sensex declined 0.41% on 31 Aug 2026, while Suven Life Sciences Ltd surged 7.06%, touching an intraday high of Rs 391.9. That 7.75-percentage-point outperformance over its Healthcare Services sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Suven Life Sciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 August 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trends, and technical outlook.

Extending its remarkable rally, Suven Life Sciences Ltd touched a fresh all-time high of Rs 392.75 on 24 Aug 2026, outperforming its sector and the broader market by a significant margin.

Suven Life Sciences Ltd has achieved a significant milestone by reaching a new 52-week high of Rs.379 on 21 August 2026, marking a notable surge in its stock price amid a broader market environment that saw selective gains in the healthcare services sector.

Suven Life Sciences Ltd, a prominent player in the healthcare services sector, reached a significant milestone on 21 August 2026 by touching its all-time high price of Rs.379. This achievement underscores the company’s sustained bullish momentum and marks a notable event in its stock market journey.

Surging past its previous peaks, Suven Life Sciences Ltd touched a new 52-week high of Rs 372.15 on 20 Aug 2026, marking a remarkable 57.35% gain over the past year against the Sensex’s decline of 5.28%. This milestone reflects a powerful convergence of technical momentum and sustained price strength.

Surging 11.22% on 20 Aug 2026, Suven Life Sciences Ltd touched an intraday high of Rs 367.60, closing near its 52-week peak of Rs 371.70. This rally extends a remarkable year-to-date gain of 121.52%, vastly outperforming the Sensex’s decline of 8.99% over the same period.

The Sensex advanced 0.7% on 20 Aug 2026, yet Suven Life Sciences Ltd outpaced the broader market with a 7.46% gain, touching an intraday high of Rs 354. This 6.02 percentage-point outperformance over its Healthcare Services sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Suven Life Sciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.